New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For JOSB;BBY;SNE;MW;FURX;HES;BBBY;ROP;KERX;CAT;RPRX From The Last 14 Days
Check below for free stories on JOSB;BBY;SNE;MW;FURX;HES;BBBY;ROP;KERX;CAT;RPRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 8, 2014
10:42 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CONN CIEN INSM FNSR PAY PVH SWY
10:06 EDTKERXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:29 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital
Subscribe for More Information
09:18 EDTKERXKeryx price target raised to $32 from $30 at Roth Capital
Subscribe for More Information
09:12 EDTKERXOn The Fly: Pre-market Movers
Subscribe for More Information
07:38 EDTKERXKeryx label for ferric citrate incrementally negative, says JPMorgan
JPMorgan says the approved label for Keryx's ferric citrate is incrementally negative given the lack of clear articulation of ESA/IV iron sparing data. The firm keeps an Overweight rating on the stock with a $24 price target, saying Keryx's 2024 patents are strong.
06:26 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital
06:21 EDTBBYSmartwatch market to reach $10B by 2018, says Citigroup
Subscribe for More Information
September 5, 2014
14:39 EDTKERXKeryx falls after FDA approves drug with warnings on label
Subscribe for More Information
13:56 EDTKERXKeryx bounces off low following halt, levels to watch
Subscribe for More Information
13:44 EDTKERXKeryx reopens, down 12.5% to $15.74 after FDA approval of Ferric Citrate
13:27 EDTKERXKeryx label for Ferric Citrate positive, says Maxim
Maxim views the label for Keryx' newly-approved Ferric Citrate as a positive that suggests the drug could become the category leader. The firm noted the FDA is deliberating on NCE Status for the drug, which it also views as appearing positive, since the agency has rejected others. Maxim maintains its Buy rating and $24 price target on the stock, which remains halted for trade, with trading set to resume at 1:40 pm ET.
13:20 EDTKERXKeryx to resume trading at 1:40 pm ET
Subscribe for More Information
11:19 EDTKERXKeryx receives FDA approval of Ferric Citrate
Subscribe for More Information
10:50 EDTKERXKeryx trading halted, pending news
September 4, 2014
13:59 EDTCATProgress Rail loses railcar improvement deals, WSJ says
Subscribe for More Information
12:16 EDTKERXKeryx September volatility elevated into PDUFA date for Zerenex
Subscribe for More Information
12:08 EDTKERXAnalysts split on Keryx ahead of FDA action date
Subscribe for More Information
08:30 EDTKERXFBR not a buyer of Keryx ahead of PDUFA date
Subscribe for More Information
07:36 EDTRPRXRepros Therapeutics weakness a buying opportunity, says Brean Capital
Brean Capital said the recent weakness in Repros Therapeutics is a buying opportunity. The firm said concerns over the upcoming FDA meeting are overblown and shares were substantially oversold in response to negative commentary yesterday. Shares of Repros Therapeutics remain Buy rated with a $41 price target.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use